Navigation Links
CHI Vice President Provides Testimony On Patient, Physician Notification of Biosimilar Substitution
Date:4/8/2013

La Jolla, CA (PRWEB) April 08, 2013

California Healthcare Institute (CHI) Vice President of State Government Affairs Eve Bukowski today provided testimony before the Senate Business, Professions and Economic Development Committee on the importance of notifying physicians when a patient’s biologic prescription has been substituted with a biosimilar drug.

Bukowski, who was diagnosed with stage-four colon cancer, spoke from personal experience and urged the committee to consider patients in the process.

“All of us with diseases treated with biologic medicines understand the instability of our health and the risks of side effects associated with our treatments. It’s a risk we are willing to take for the benefits we receive,” Bukowski said. “Informing the physician of a substitution is not only consistent with current pharmacist-physician interaction, it’s a simple precautionary step.”

Unlike their pharmaceutical counterparts, biotech drugs are made from living organisms and derive from more complex manufacturing processes involving sensitive fermentation and purification. Biosimilars are products “highly similar to” or “interchangeable” with a U.S. Food and Drug Administration-licensed biological product.

New legislation known as SB 598 and authored by Sen. Jerry Hill (D-San Mateo) would regulate the dispensing of biosimilars. It would require patient and physician notification of biosimilar substitution and that the full name and manufacturer be indicated on the medicine’s label.

“SB 598 recognizes that because biologic medicines are not the same as chemically-based generic medicines they need their own set of rules,” Bukowski said.

The committee also heard from Geoffrey Eich, executive director of regulatory affairs at Amgen.

California is known as the “birthplace of biotechnology,” where life-saving biologics such as Avastin and Epogen were developed. The state’s biopharmaceutical industry employs 42,886 people, more than any other state in the nation. The industry is responsible for producing innovative products for treating heart disease, cancer, diabetes, multiple sclerosis and Alzheimer’s disease that serve to benefit millions of patients in the United States and around the world.

About CHI
CHI represents more than 275 leading biotechnology, medical device, diagnostics, and pharmaceutical companies, and public and private academic biomedical research organizations. CHI’s mission is to advance responsible public policies that foster medical innovation and promote scientific discovery. CHI’s website is http://www.chi.org. Follow us on Twitter @calhealthcare, Facebook, LinkedIn and YouTube.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10612725.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Brian Cousins Joins Opedix Joint Support Athletic Wear as Vice President of Business Development
2. Nerium New Hire - Vice President of US Operations
3. California Healthcare Institute Appoints Vice President-State Government Affairs
4. Archie Cullen Named President of BioReliance
5. BioHealth Innovation, Inc. President & CEO Richard Bendis to Present at SXSW 2013 & 2013 BIO International Convention
6. BIOCOM Names Rick Fultz Vice President of Business Development
7. AMRI Promotes Takeshi Yura, Ph.D., to Vice President of Discovery and Development Services, Asia
8. Lou Paradise, President and Chief of Research, Topical BioMedics, Inc. Slated to Speak at Integrative Healthcare Symposium
9. Cellular Biomedicine Group President Presents Keynote Address at New York Stem Cell Summit
10. Inflamax Research Appoints Dr. Anne Marie Salapatek President & Chief Scientific Officer
11. Society for Brain Mapping and Therapeutics endorse President Obamas support for Human Brain Mapping research; nominating him for prestigious Pioneer in Healthcare Policy Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Summary This report provides all the information you ... and activities since 2010. Description The Partnering Deals and ... partnering activity of one of the world,s leading life sciences ... purchase to ensure inclusion of the most up to date ... delivered in PDF format within 1 working day of receipt ...
(Date:3/28/2017)... 28, 2017 Dr. Chris Yu ... corporation Anpac Bio-Medical Science Company , announced ... record, processing and reporting over 40,000 cases worldwide ... (CDA) liquid biopsy tests. Described ... Summit publications, Anpac Bio,s CDA medical devices and ...
(Date:3/28/2017)... , ... March 28, 2017 ... ... launch its brand-new, fully-certified hygienic SWB805 MultiMountTM weigh modules. These weigh modules ... and certified by National Sanitation Foundation (NSF). , As fully integrated weighing ...
(Date:3/27/2017)... ... March 27, 2017 , ... IsoPlexis ... against cancer, autoimmune disease and more through a single-cell precision engineering platform, today ... analysis platform developed in the laboratory of Dr. James Heath at the ...
Breaking Biology Technology:
(Date:3/2/2017)... Australia , March 2, 2017 Australian ... Ltd (ASX: CYP), has signed an agreement with ... from the Monash Biomedicine Discovery Institute and Department of ... to conduct a further preclinical study to support the ... treatment of asthma.  Asthma is a ...
(Date:2/27/2017)...   Strategic Cyber Ventures , the industry,s first ... $3.5 million investment in  Polarity , the first commercial ... DC based and is led by cybersecurity veterans ... Ron Gula , also a longtime cybersecurity veteran and ... series A round of funding. This new funding will ...
(Date:2/21/2017)... 2017 Der weltweite Biobanking-Sektor wird ... einem Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen ... gilt, um diese Prognose zu realisieren. ... Zu den ... finanziellen Mittel für die Biobank, die Implementierung Zeit sparender ...
Breaking Biology News(10 mins):